Stockreport

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Xilio Therapeutics, Inc.  (XLO) 
PDF Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-brea [Read more]